• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
International expert consensus on immunotherapy for early-stage non-small cell lung cancer.早期非小细胞肺癌免疫治疗的国际专家共识
Transl Lung Cancer Res. 2022 Sep;11(9):1742-1762. doi: 10.21037/tlcr-22-617.
2
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).癌症免疫治疗学会关于免疫治疗非小细胞肺癌（NSCLC）的共识声明。
J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.
3
[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].《中国非小细胞肺癌PD-L1表达检测专家共识》
Zhonghua Zhong Liu Za Zhi. 2020 Jul 23;42(7):513-521. doi: 10.3760/cma.j.cn112152-20200313-00202.
4
Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study.立体定向消融放疗后早期非小细胞肺癌的最佳影像学监测：一项国际德尔菲共识研究的结果。
Pract Radiat Oncol. 2018 Mar-Apr;8(2):e71-e78. doi: 10.1016/j.prro.2017.10.008. Epub 2017 Dec 30.
5
[Chinese expert consensus on stereotactic body radiation therapy for early stage non-small cell lung cancer (2019 Edition)].《中国早期非小细胞肺癌立体定向体部放射治疗专家共识（2019版）》
Zhonghua Zhong Liu Za Zhi. 2020 Jul 23;42(7):522-530. doi: 10.3760/cma.j.cn112152-20200116-00039.
6
[Chinese expert consensus on the multidisciplinary clinical diagnosis and treatment of stage Ⅲ non-small cell lung cancer (2019)].《中国Ⅲ期非小细胞肺癌多学科临床诊断与治疗专家共识（2019年版）》
Zhonghua Zhong Liu Za Zhi. 2019 Dec 23;41(12):881-890. doi: 10.3760/cma.j.issn.0253-3766.2019.12.001.
7
Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document.Ⅰ期非小细胞肺癌行肺叶切除术患者高危因素的定义和评估：美国胸外科学会专家组共识文件。
J Thorac Cardiovasc Surg. 2021 Dec;162(6):1605-1618.e6. doi: 10.1016/j.jtcvs.2021.07.030. Epub 2021 Jul 29.
8
Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.免疫相关缓解标准在非小细胞肺癌免疫治疗疗效评价中的应用共识。
Clin Transl Oncol. 2019 Nov;21(11):1464-1471. doi: 10.1007/s12094-019-02072-4. Epub 2019 Mar 22.
9
[Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].《中国晚期非小细胞肺癌抗血管生成药物专家共识（2020年版）》
Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1063-1077. doi: 10.3760/cma.j.cn112152-20200918-00836.
10
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.非小细胞肺癌的免疫治疗：来自意大利胸科肿瘤学协会国际专家小组会议的报告
Expert Opin Biol Ther. 2016 Dec;16(12):1479-1489. doi: 10.1080/14712598.2016.1234602. Epub 2016 Sep 21.

引用本文的文献

1
Curative intent therapy of stage I-III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms.I-III期非小细胞肺癌的根治性意向治疗：一种以患者为中心的精准方法，用于评估、衡量和解释获益与危害。
J Thorac Dis. 2025 Jul 31;17(7):4473-4500. doi: 10.21037/jtd-2025-213. Epub 2025 Jul 29.
2
Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.可切除的 III 期非小细胞肺癌患者在新辅助化疗免疫治疗后辅助免疫治疗是否必要？一项双中心真实世界研究。
Cancer Immunol Immunother. 2025 Jul 21;74(8):273. doi: 10.1007/s00262-025-04130-z.
3
Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review.与免疫检查点抑制剂使用相关的免疫性溶血性贫血：一项范围综述
Front Immunol. 2025 Jul 3;16:1586426. doi: 10.3389/fimmu.2025.1586426. eCollection 2025.
4
Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study.诱导化疗免疫疗法在不可切除的 III 期非小细胞肺癌患者中可能取得与巩固免疫疗法非劣效的结果：一项真实世界多中心回顾性研究。
Front Immunol. 2025 Jun 12;16:1591134. doi: 10.3389/fimmu.2025.1591134. eCollection 2025.
5
Simultaneous immunomodulation and epithelial-to-mesenchymal transition drives lung adenocarcinoma progression.同时发生的免疫调节和上皮-间质转化驱动肺腺癌进展。
bioRxiv. 2025 Feb 22:2025.02.19.637138. doi: 10.1101/2025.02.19.637138.
6
Mapping the evolution and frontiers of : a bibliometric analysis and literature review.绘制：的演变与前沿：文献计量分析与文献综述 （原句中冒号前内容不完整）
Transl Lung Cancer Res. 2024 Dec 31;13(12):3764-3777. doi: 10.21037/tlcr-24-653. Epub 2024 Dec 27.
7
Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer.纳武利尤单抗联合铂类新辅助化疗用于非小细胞肺癌的真实世界临床结局
J Clin Med. 2024 Oct 31;13(21):6568. doi: 10.3390/jcm13216568.
8
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.可切除非小细胞肺癌的新辅助和辅助免疫治疗
Cancers (Basel). 2024 Apr 23;16(9):1619. doi: 10.3390/cancers16091619.
9
The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer.早期非小细胞肺癌围手术期免疫治疗时代的开端。
Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. doi: 10.21037/tlcr-23-470. Epub 2023 Nov 1.
10
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.新辅助治疗后肺癌病理缓解与生存的关系。
Nat Med. 2024 Jan;30(1):218-228. doi: 10.1038/s41591-023-02660-6. Epub 2023 Oct 30.

本文引用的文献

1
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.可切除非小细胞肺癌的新辅助阿替利珠单抗治疗：一项开放标签、单臂 II 期试验。
Nat Med. 2022 Oct;28(10):2155-2161. doi: 10.1038/s41591-022-01962-5. Epub 2022 Sep 12.
2
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.新辅助化疗联合免疫治疗早期可切除非小细胞肺癌。
J Clin Oncol. 2022 Sep 1;40(25):2871-2877. doi: 10.1200/JCO.22.00873. Epub 2022 Jun 17.
3
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).新辅助纳武利尤单抗联合化疗治疗可手术 IIIA 期非小细胞肺癌的总生存和生物标志物分析（NADIM Ⅱ期试验）。
J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16.
4
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
5
Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.化疗联合PD-1/PD-L1阻断疗法应成为非小细胞肺癌新辅助治疗的首选方案。
J Thorac Oncol. 2022 Apr;17(4):503-509. doi: 10.1016/j.jtho.2022.02.007.
6
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.新辅助纳武利尤单抗或纳武利尤单抗联合伊匹单抗治疗非小细胞肺癌患者的手术结局。
J Thorac Cardiovasc Surg. 2022 Nov;164(5):1327-1337. doi: 10.1016/j.jtcvs.2022.01.019. Epub 2022 Jan 23.
7
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.PACIFIC试验的五年生存结果：III期非小细胞肺癌放化疗后使用度伐利尤单抗治疗
J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.
8
Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature.辅助化疗在现实临床实践中用于可切除非小细胞肺癌的情况：一项文献系统综述
Transl Lung Cancer Res. 2021 Dec;10(12):4643-4665. doi: 10.21037/tlcr-21-557.
9
Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.局部晚期、III 期 A/B-N2 期非小细胞肺癌的外科或医学治疗策略：多学科肿瘤委员会决策的可重复性。
Lung Cancer. 2022 Jan;163:51-58. doi: 10.1016/j.lungcan.2021.12.004. Epub 2021 Dec 10.
10
Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer.可切除非小细胞肺癌新辅助免疫治疗的荟萃分析。
Curr Oncol. 2021 Nov 14;28(6):4686-4701. doi: 10.3390/curroncol28060395.

International expert consensus on immunotherapy for early-stage non-small cell lung cancer.

作者信息

Liang Wenhua, Cai Kaican, Cao Qingdong, Chen Chun, Chen Haiquan, Chen Jun, Chen Ke-Neng, Chen Qixun, Chu Tianqing, Dong Yuchao, Fan Jiang, Fang Wentao, Fu Junke, Fu Xiangning, Gao Shugeng, Ge Di, Geng Guojun, Geng Qing, He Jie, Hu Jian, Hu Jie, Hu Wei-Dong, Jiang Feng, Jiang Tao, Jiao Wenjie, Li He-Cheng, Li Qiang, Li Shanqing, Li Shuben, Li Xiangnan, Liao Yong-De, Liu Changhong, Liu Hongxu, Liu Yang, Lu Zhuming, Luo Qingquan, Ma Haitao, Pan Xiaojie, Qiao Guibin, Ren Shengxiang, Shen Weiyu, Song Yong, Sun Daqiang, Wang Guangsuo, Wang Jie, Wang Mengzhao, Wang Qiwen, Wang Wen-Xiang, Wei Li, Wu Ming, Wu Nan, Xia Hui, Xu Shi-Dong, Yang Fan, Yang Kang, Yang Yue, Yu Fenglei, Yu Zhen-Tao, Yue Dong-Sheng, Zhang Lanjun, Zhang Weidong, Zhang Zhenfa, Zhao Guofang, Zhao Jian, Zhao Xiaojing, Zhou Chengzhi, Zhou Qinghua, Zhu Kunshou, Zhu Yuming, Hida Toyoaki, Dempke Wolfram C M, Rossi Antonio, de Perrot Marc, Ramirez Robert A, Provencio Mariano, Lee Jay M, Passaro Antonio, Spaggiari Lorenzo, Spicer Jonathan, Girard Nicolas, Forde Patrick M, Mok Tony S K, Cascone Tina, He Jianxing

机构信息

Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China.

Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

出版信息

Transl Lung Cancer Res. 2022 Sep;11(9):1742-1762. doi: 10.21037/tlcr-22-617.

DOI:10.21037/tlcr-22-617
PMID:36248334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9554679/
Abstract
摘要